molecular formula C46H56N4O10 B1662923 Vincristine CAS No. 57-22-7

Vincristine

カタログ番号: B1662923
CAS番号: 57-22-7
分子量: 825.0 g/mol
InChIキー: OGWKCGZFUXNPDA-DLBZMDDPSA-N
注意: 研究専用です。人間または獣医用ではありません。
在庫あり
  • 専門家チームからの見積もりを受け取るには、QUICK INQUIRYをクリックしてください。
  • 品質商品を競争力のある価格で提供し、研究に集中できます。

科学的研究の応用

Clinical Applications

Vincristine is approved for treating various malignancies, including:

  • Acute Lymphoblastic Leukemia (ALL)
  • Hodgkin's and Non-Hodgkin Lymphomas
  • Neuroblastoma
  • Wilms Tumor
  • Rhabdomyosarcoma
  • Kaposi Sarcoma

FDA-Approved Indications

Cancer TypeFDA Approval Year
Acute Lymphoblastic Leukemia1963
Wilms Tumor1963
Hodgkin's Lymphoma1963
Non-Hodgkin Lymphoma1963
Rhabdomyosarcoma1963

Off-Label Uses

In addition to its approved indications, this compound is used off-label for:

  • Central Nervous System (CNS) tumors
  • Ewing Sarcoma
  • Medulloblastoma
  • Bladder Cancer
  • Ovarian Cancer

Combination Therapies

This compound is often used in combination with other chemotherapeutic agents to enhance efficacy while minimizing adverse effects. Notable combination regimens include:

  • CHOP : Cyclophosphamide, Doxorubicin, this compound, Prednisolone
  • CVP : Cyclophosphamide, this compound, Prednisolone
  • CISCA : Cisplatin, Doxorubicin, Vinblastine, Bleomycin

Case Studies and Clinical Trials

Numerous studies underscore this compound's effectiveness across different cancer types. A notable trial reported that this compound administered weekly to children with advanced cancer resulted in a 68% objective tumor response rate across various malignancies, including ALL and Hodgkin's disease .

Clinical Trial Insights

Study FocusFindings
This compound in Advanced Cancer68% response rate in pediatric patients
Combination Therapy with this compoundEnhanced efficacy in lymphoma treatments

Pharmacokinetics and Challenges

This compound's pharmacokinetic profile reveals rapid distribution and significant protein binding (approximately 75%). However, its clinical use is limited by neurotoxicity and other side effects such as alopecia and constipation. Recent advancements focus on improving its delivery through nanotechnology-based formulations to enhance targeting and reduce toxicity .

Emerging Trends

Research continues to explore this compound's role in combination therapies and novel formulations. For instance, liposomal formulations like Marqibo have been developed to prolong circulation time and improve dosing efficacy for patients with relapsed ALL . Additionally, ongoing studies are investigating its use in treating solid tumors and enhancing its therapeutic index through innovative drug delivery systems .

特性

CAS番号

57-22-7

分子式

C46H56N4O10

分子量

825.0 g/mol

IUPAC名

methyl (10S,11R,12R)-11-acetyloxy-12-ethyl-4-[(13S,15S,17S)-17-ethyl-17-hydroxy-13-methoxycarbonyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraen-13-yl]-8-formyl-10-hydroxy-5-methoxy-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate

InChI

InChI=1S/C46H56N4O10/c1-7-42(55)22-28-23-45(40(53)58-5,36-30(14-18-48(24-28)25-42)29-12-9-10-13-33(29)47-36)32-20-31-34(21-35(32)57-4)50(26-51)38-44(31)16-19-49-17-11-15-43(8-2,37(44)49)39(60-27(3)52)46(38,56)41(54)59-6/h9-13,15,20-21,26,28,37-39,47,55-56H,7-8,14,16-19,22-25H2,1-6H3/t28-,37?,38?,39-,42+,43-,44?,45+,46+/m1/s1

InChIキー

OGWKCGZFUXNPDA-DLBZMDDPSA-N

不純物

3'-hydroxyvincristine;  4'-deoxyvincristine;  N-desmethylvinblastine;  deacetylvincristine;  deacetylvinblastine;  vinblastine;  leurosine;  formylleurosine

SMILES

CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O

異性体SMILES

CC[C@@]1(C[C@@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7[C@@](C=CC9)([C@H]([C@@](C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O

正規SMILES

CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O

外観

White to off-white, odorless amorphous or crystalline powder

Color/Form

Blades from methanol

melting_point

424 to 428 °F (NTP, 1992)
218-220 °C

Key on ui other cas no.

57-22-7

物理的記述

Vincristine appears as a white crystalline solid. Melting point 218 °C. Used as an antineoplastic.

賞味期限

STERILE SOLN IN EITHER H2O OR PHYSIOLOGICAL SALINE STORED IN REFRIGERATOR FOR UP TO 2 WK WITHOUT SIGNIFICANT LOSS OF POTENCY

溶解性

WHITE TO SLIGHTLY YELLOW, AMORPHOUS OR CRYSTALLINE POWDER;  ODORLESS, HYGROSCOPIC;  FREELY SOL IN WATER /VINCRISTINE SULFATE USP/

同義語

cellcristin
Citomid
Farmistin
Leurocristine
Oncovin
Oncovine
Onkocristin
PFS, Vincasar
Sulfate, Vincristine
Vincasar
Vincasar PFS
Vincristin Bristol
Vincristin medac
Vincristine
Vincristine Sulfate
Vincrisul
Vintec

製品の起源

United States

Retrosynthesis Analysis

AI-Powered Synthesis Planning: Our tool employs the Template_relevance Pistachio, Template_relevance Bkms_metabolic, Template_relevance Pistachio_ringbreaker, Template_relevance Reaxys, Template_relevance Reaxys_biocatalysis model, leveraging a vast database of chemical reactions to predict feasible synthetic routes.

One-Step Synthesis Focus: Specifically designed for one-step synthesis, it provides concise and direct routes for your target compounds, streamlining the synthesis process.

Accurate Predictions: Utilizing the extensive PISTACHIO, BKMS_METABOLIC, PISTACHIO_RINGBREAKER, REAXYS, REAXYS_BIOCATALYSIS database, our tool offers high-accuracy predictions, reflecting the latest in chemical research and data.

Strategy Settings

Precursor scoring Relevance Heuristic
Min. plausibility 0.01
Model Template_relevance
Template Set Pistachio/Bkms_metabolic/Pistachio_ringbreaker/Reaxys/Reaxys_biocatalysis
Top-N result to add to graph 6

Feasible Synthetic Routes

Reactant of Route 1
Vincristine
Reactant of Route 2
Vincristine
Reactant of Route 3
Vincristine
Reactant of Route 4
Vincristine
Reactant of Route 5
Vincristine
Reactant of Route 6
Vincristine

試験管内研究製品の免責事項と情報

BenchChemで提示されるすべての記事および製品情報は、情報提供を目的としています。BenchChemで購入可能な製品は、生体外研究のために特別に設計されています。生体外研究は、ラテン語の "in glass" に由来し、生物体の外で行われる実験を指します。これらの製品は医薬品または薬として分類されておらず、FDAから任何の医療状態、病気、または疾患の予防、治療、または治癒のために承認されていません。これらの製品を人間または動物に体内に導入する形態は、法律により厳格に禁止されています。これらのガイドラインに従うことは、研究と実験において法的および倫理的な基準の遵守を確実にするために重要です。